Date: 2016-03-30
Type of information: Licensing agreement
Compound: blood-based lung cancer test
Company: Epigenomics (Germany - USA) BioChain (USA - CA - China)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: licensing
Action mechanism:
Disease: lung cancer
Details: * On March 30, 2016, Epigenomics announced that it has entered a strategic license agreement with BioChain on the development and commercialization of a novel, blood-based lung cancer test for China. BioChain will initiate a clinical trial to validate the lung cancer detection test with the goal to gain market approval by the CFDA. The trial is expected to start in 2016. The product development will be based on Epigenomics’ novel panel of blood-based DNA methylation biomarkers that has shown promising results in a clinical validation study.
Financial terms: Under the terms of the agreement, Epigenomics will receive undisclosed upfront, milestone and minimum annual payments as well as mid single-digit royalty on future revenues.
Latest news:
